Success Story: A Postdoctoral Fellow from Rwanda Secures EB-2 NIW Approval After 17 Months Without an RFE

 

Client’s Testimonial:

“Thanks for the help during all the processes.”


On February 16th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Fellow in the Field of Non-Communicable Diseases (Approval Notice).


General Field: Non-Communicable Diseases

Position at the Time of Case Filing: Postdoctoral Fellow

Country of Origin: Rwanda

State of Residence at the Time of Filing: Georgia

Approval Notice Date: February 16th, 2026

Processing Time: 17 months, 22 days


Case Summary:  

It was a privilege for our team to assist a postdoctoral fellow from Rwanda specializing in non-communicable diseases with an EB-2 NIW petition. Drawing on our extensive experience and a proven track record of over 32,000 successful cases, this case demonstrates our commitment to I-140 clients through strategic, case-by-case analysis and meticulous petition development. The petition achieved approval after 17 months without an RFE.

Building the Foundation

The client holds a Ph.D. in biology and works as a postdoctoral fellow, leveraging advanced sequencing technologies. Their research aims to develop enhanced pharmaceuticals and therapeutics that improve patient outcomes and reduce healthcare costs associated with heart disease.

Our team's initial assessment identified several compelling strengths: an outstanding publication portfolio in top-ranked journals and extraordinary citation metrics reflecting global field influence. Notably, one paper ranked in the top 0.01% and another in the top 1% of the most cited articles for their respective publication years. The case also demonstrated strong alignment with federal priorities.

We documented the client's impressive metrics: 11,466 citations and 14 peer-reviewed journal articles (including 3 first-authored). Through this work, the client has made significant contributions, including devising widely adopted guidelines for autophagy assays, identifying a novel long noncoding RNA that accelerates vascular disease development, and demonstrating that autophagy-targeted therapy can suppress tumor progression.

NIW Approval and Outlook

This outcome underscores our continued success in securing approvals for researchers whose work bridges molecular biology, cardiovascular medicine, and public health. The client's ongoing research into the molecular mechanisms of cardiovascular diseases continues to drive progress toward improved therapeutics and reduced healthcare burden, aligning closely with the United States' long-term goals of innovation, health security, and technological leadership in biomedical research.